(1S,2R,5S,6S,9R,10R,11S,13R,15S)-11,13-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[(4-ethyl-4-triethylsilyloxyhexoxy)methyl]-6,10-dimethyl-18-phenyl-16,18,20-triazahexacyclo[13.5.2.01,9.02,6.010,15.016,20]docos-21-ene-17,19-dione | 368878-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (1S,2R,5S,6S,9R,10R,11S,13R,15S)-11,13-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[(4-ethyl-4-triethylsilyloxyhexoxy)methyl]-6,10-dimethyl-18-phenyl-16,18,20-triazahexacyclo[13.5.2.01,9.02,6.010,15.016,20]docos-21-ene-17,19-dione
• CAS: 368878-09-5
• 化学式: C₅₄H₉₃N₃O₆Si₃
• 分子量: 964.605
• InChiKey: LSFXRMGEEHXGRY-PQKZNBJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  13.18
• 重原子数：
  66
• 可旋转键数：
  20
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  80.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (1S,2R,5S,6S,9R,10R,11S,13R,15S)-11,13-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[(4-ethyl-4-triethylsilyloxyhexoxy)methyl]-6,10-dimethyl-18-phenyl-16,18,20-triazahexacyclo[13.5.2.01,9.02,6.010,15.016,20]docos-21-ene-17,19-dione 在 地昔帕明 、 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 1α,3β-dihydroxy-17β-(4-ethyl-4-hydroxyhexyloxymethyl)androsta-5,7-diene
  参考文献：
  名称：

  Synthesis of 21-nor-22-oxa-1α,25-dihydroxyvitamin D3 derivatives in quest of a drug with low calcemic activity

  摘要：

  Two 21-nor-22-oxa- 1alpha,25-dihydroxyvitamin D-3 derivatives have been synthesized in quest of a drug with lower calcemic activity than Maxacalcitol, 22-oxa-1alpha,25-dihydroxyvitamin D-3, being used as antihyperparathyroidism and antipsoriatic drug. Of two 21-nor products obtained, the product carrying one carbon elongated side chain with diethylcarbinol moiety has been found to exhibit comparable differentiation-inducing activity to Maxacalcitol with much lower exhibition of calcemic activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.08.160
• 作为产物：
  描述：

  1α,3β-bis<(tert-butyldimethylsilyl)oxy>androst-5-en-17-one 在 2,4,6-三甲基吡啶 、 N-溴代丁二酰亚胺(NBS) 、 9-borabicyclo[3.3.1]nonane dimer 、 18-冠醚-6 、 偶氮二异丁腈 、 potassium tert-butylate 、 sodium hydride 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 生成 (1S,2R,5S,6S,9R,10R,11S,13R,15S)-11,13-bis[[tert-butyl(dimethyl)silyl]oxy]-5-[(4-ethyl-4-triethylsilyloxyhexoxy)methyl]-6,10-dimethyl-18-phenyl-16,18,20-triazahexacyclo[13.5.2.01,9.02,6.010,15.016,20]docos-21-ene-17,19-dione
  参考文献：
  名称：

  Synthesis of 21-nor-22-oxa-1α,25-dihydroxyvitamin D3 derivatives in quest of a drug with low calcemic activity

  摘要：

  Two 21-nor-22-oxa- 1alpha,25-dihydroxyvitamin D-3 derivatives have been synthesized in quest of a drug with lower calcemic activity than Maxacalcitol, 22-oxa-1alpha,25-dihydroxyvitamin D-3, being used as antihyperparathyroidism and antipsoriatic drug. Of two 21-nor products obtained, the product carrying one carbon elongated side chain with diethylcarbinol moiety has been found to exhibit comparable differentiation-inducing activity to Maxacalcitol with much lower exhibition of calcemic activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.08.160

文献信息

• Synthesis of 21-nor-22-oxa-1α,25-dihydroxyvitamin D3 derivatives in quest of a drug with low calcemic activity
  作者：Hitoshi Shimizu、Kazuki Shimizu、Yasushi Uchiyama、Atsuko Sugita、Tetsuhiro Mikami、Tsuyoshi Yamauchi、Masahiro Kato、Kazumi Morikawa

  DOI：10.1016/j.tetlet.2004.08.160

  日期：2004.10

  Two 21-nor-22-oxa- 1alpha,25-dihydroxyvitamin D-3 derivatives have been synthesized in quest of a drug with lower calcemic activity than Maxacalcitol, 22-oxa-1alpha,25-dihydroxyvitamin D-3, being used as antihyperparathyroidism and antipsoriatic drug. Of two 21-nor products obtained, the product carrying one carbon elongated side chain with diethylcarbinol moiety has been found to exhibit comparable differentiation-inducing activity to Maxacalcitol with much lower exhibition of calcemic activity. (C) 2004 Elsevier Ltd. All rights reserved.